A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors

To join this study, adults must be at least 18 years old and have a solid tumour cancer (like breast cancer or other types) that has been medically confirmed to have the 'AKT1 E17K' genetic change. This genetic change would have been found through specific tests. Your cancer would also need to be advanced, meaning it's spread or can't be removed, and you would have already tried standard treatments that didn't work, couldn't be tolerated, or you chose not to have them.

There are also some health requirements, such as being generally well enough to take part and having important organs (like your liver and kidneys) working properly. Doctors will also need to be able to measure or assess your cancer to see how it responds to the treatment.

However, some things would prevent you from joining. For example, if you've already had certain drugs that work in a similar way (PI3K or mTOR inhibitors) or if your cancer has different specific genetic changes (like KRAS, NRAS, HRAS, or BRAF). You also wouldn't be able to join if you have a condition making it hard to swallow or absorb oral medication, as ALTA2618 is a tablet. Your study doctor will review all criteria to see if this study is right for you.

If you decide to take part, you would receive the study medication, ALTA2618, as a tablet. You would have regular visits to the study clinic for check-ups, blood tests, and scans to monitor your health and how the medicine is affecting your cancer. These tests will help doctors understand how your body handles the medicine and if it's having any effect on your tumour. The visits would be more frequent at the beginning of the study, especially during the dose-finding part, and might become less frequent later on. The total length of your participation would depend on how your cancer responds and how you tolerate the treatment, but you would be followed up regularly. Your study team would explain the exact schedule in detail.